MedTrace Logo

Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC

NCT07184424 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-09-19

No results posted yet for this study

Summary

This study is a real-world, single-arm, observational study primarily collecting data on patients with hepatocellular carcinoma who experienced disease progression after receiving lenvatinib in combination with PD-1 inhibitors as part of routine clinical practice, and evaluating the efficacy of adding lenalidomide to their treatment regimen.

Conditions

  • HCC - Hepatocellular Carcinoma

Interventions

DRUG

lenalidomide

For patients with hepatocellular carcinoma who have experienced disease progression after receiving standard clinical treatment with lenvatinib in combination with PD-1 inhibitors, the addition of lenalidomide capsules to the three-drug combination therapy was followed by a 2-month follow-up liver imaging examination to observe changes in the target lesion and whether new lesions had developed in other areas.

Sponsors & Collaborators

  • Beijing Tsinghua Chang Gung Hospital

    lead OTHER

Principal Investigators

  • GONG LI, phD · Beijing Tsinghua Changgeng Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-24
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07184424 on ClinicalTrials.gov